EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Toxicities from BRAF and MEK Inhibitors: Strategies to Maximize Therapeutic Success

Mike Wang, Ryan J Sullivan, Meghan J Mooradian

Current Oncology Reports · 2024

DOI: 10.1007/s11912-024-01544-3 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology Reports, 2024. Verfasst von Mike Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Protein Kinase Inhibitors, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 55 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE OF REVIEW: This report highlights several of the recent therapeutic advancements in the treatment of BRAF-mutant tumors, discusses the most common adverse events observed with BRAF-targeted agents, and suggests strategies to manage and mitigate treatment-related toxicities. RECENT FINDINGS: BRAF and MEK inhibitors represent a significant advancement in the treatment of BRAF-mutated malignancies with data across tumor types demonstrating the anti-tumor efficacy of dual MAPK inhibition. Although these agents have a reasonable toxicity profile, variable side effects across organ systems can develop. The discovery of activating BRAF mutations and subsequent development of BRAF and MEK inhibitors has transformed the treatment algorithms of BRAF-mutant malignancies. With increased application of these targeted regimens, identification and prompt management of their unique adverse events are crucial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins B-rafProtein Kinase InhibitorsNeoplasmsHumansMutationAntineoplastic AgentsMitogen-Activated Protein Kinase KinasesMolecular Targeted Therapy

Stichwörter der Autor:innen

BRAF inhibitionBRAF mutationMEK inhibitionMelanomaNSCLCToxicity

Substanzen

Proto-Oncogene Proteins B-rafProtein Kinase InhibitorsBRAF protein, humanAntineoplastic AgentsMitogen-Activated Protein Kinase Kinases

Autor:innen und Institutionen

  • Division of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA.
  • Harvard Medical School, Boston, MA, USA.
  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
  • Division of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA. mmooradian@mgh.harvard.edu.
  • Harvard Medical School, Boston, MA, USA. mmooradian@mgh.harvard.edu.

Zitieren

APA

Wang, M., Sullivan, R. J., & Mooradian, M. J. (2024). Toxicities from BRAF and MEK Inhibitors: Strategies to Maximize Therapeutic Success. Current Oncology Reports. https://doi.org/10.1007/s11912-024-01544-3

Vancouver

Wang M, Sullivan RJ, Mooradian MJ. Toxicities from BRAF and MEK Inhibitors: Strategies to Maximize Therapeutic Success. Current Oncology Reports. 2024. doi:10.1007/s11912-024-01544-3

BibTeX
@article{Wang2024,
  author = {Wang, Mike and Sullivan, Ryan J and Mooradian, Meghan J},
  title = {Toxicities from BRAF and MEK Inhibitors: Strategies to Maximize Therapeutic Success},
  journal = {Current Oncology Reports},
  year = {2024},
  doi = {10.1007/s11912-024-01544-3}
}
Kostenlos starten →